A real-world non-interventional study to assess patient satisfaction with and preference for re-usable Respimat Soft Mist inhaler in patients with chronic obstructive pulmonary disease

Study identification

• EU PAS number:
  EUPAS30293
• Study ID:
  36207
• Official title and acronym:
  A real-world non-interventional study to assess patient satisfaction with and preference for re-usable Respimat Soft Mist inhaler in patients with chronic obstructive pulmonary disease
• DARWIN EU® study:
  No
• Study countries:
  Belgium

  Denmark

  Finland

  Germany

  Netherlands

  Norway
• Study description:
  A real-world non-interventional study to assess patient satisfaction with inhaler attributes of the re-usable Respimat® Soft MistTM Inhaler (SMI) in adult patients with chronic obstructive pulmonary disease (COPD),including patients who are Respimat SMI-experienced and Respimat SMI-naïve. This study also aims to examine patient preference for the re-usable Respimat SMI compared to the disposable Respimat SMI in Respimat SMI-experienced patients switching from a disposable toa re-usable Respimat SMI product at study entry
• Study status:
  Finalised

Research institutions and networks

Institutions

Boehringer Ingelheim

Multiple centres: 22 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 25/09/2019

Actual: 17/09/2019

Study start date

Planned: 30/09/2019

Actual: 07/10/2019

Data analysis start date

Planned: 12/03/2020

Actual: 06/03/2020

Date of final study report

Planned: 29/06/2020

Actual: 22/06/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Boehringer Ingelheim International GmbH

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable